| This week's sponsor is SynteractHCR. | | | |
Today's Rundown GlaxoSmithKline R&D chief Vallance to leave for government job: FT Witty to head up new U.K. speedy drug/device review system Republican tax reforms could hit rare-disease research [Sponsored] Mitotech: a (very) different approach to treating Dry Eye Investors crown Alnylam winner of face-off against Ionis Novartis, Amgen and Banner aim for Alzheimer’s prevention with new BACE trials A child's own umbilical cord blood may ease cerebral palsy EuroBiotech Report—AstraZeneca’s busy week, Big Pharma help Euro VC fund go big and Boehringer places NASH bet FiercePharmaAsia—Daiichi cancer test result, Samsung’s profit, Astellas’ corporate ad Chutes & Ladders—Grail bids farewell to a trio of top executives Featured Story | | | Friday, November 3, 2017 GlaxoSmithKline’s long-standing president of R&D, Patrick Vallance, is said to be standing down. Vallance, who has been at the helm of the Big Pharma’s research for around six years, is purportedly leaving for a top science advisory post for the U.K. government. |
|
|
| This week's sponsor is Deloitte. | | | |
Top Stories Friday, November 3, 2017 The U.K. government has announced that former GlaxoSmithKline chief Sir Andrew Witty will head up its new pathway that aims to get a handful of drugs and medical technologies to patients quicker than ever before. Friday, November 3, 2017 A tax credit that allows biopharma companies to recoup some of the cost of developing drugs for rare diseases could be abolished if a Republican tax reform bill goes through. Monday, October 30, 2017 Approximately 16 million Americans have been told by their doctor that they have Dry Eye Disease – the itchy, uncomfortable and inconvenient condition that remains the number one reason people go see an ophthalmologist. Friday, November 3, 2017 Alnylam has emerged victorious from its hereditary TTR amyloidosis (hATTR) data face-off against Ionis. Data presented by the RNAi pioneer suggest its patisiran has the edge over Ionis’ inotersen in terms of safety and efficacy, although it remains to be seen whether this translates into market share. Thursday, November 2, 2017 It’s a depressingly familiar story in Alzheimer’s R&D: a lot of hype, sprinkles of hope, but then dashed when data day comes around. Thursday, November 2, 2017 Umbilical cord blood is FDA-approved for the treatment of blood-related disorders, such as sickle cell disease. Now a team at Duke may have landed on a new application for cord blood: improving motor skills in children with cerebral palsy. Thursday, November 2, 2017 In this week's EuroBiotech Report, AstraZeneca's pipeline evolves, Bristol-Myers and Johnson & Johnson back VC fund, Boehringer pens a NASH deal and more. Friday, November 3, 2017 Daiichi Sankyo released limited results from an enrollment-suspended cancer trial and formed an antibody-drug conjugate deal on Glycotope's lead antibody; Samsung BioLogics reported operating profits for the first time; plus more. Friday, November 3, 2017 Vik Bajaj left Grail as CSO and joined VC firm Foresite Capital, Aerie lured Allergan veteran John Maltman to oversee medical affairs, AMRI poached Mylan’s business development expert Paul Feuerman, plus more hirings, firings and retirings throughout the industry. Enrollment Showcase | | | Sponsored by: Drexel University Online Drexel University’s online graduate programs in biomedicine, clinical research, drug discovery, and molecular medicine were developed with working professionals in mind, providing you with the education, practical skills, and competitive edge you need to be successful in your career. Learn more. |
|
|
Resources Sponsored by: Reprints Desk SO CLOSE AND YET SO FAR. Is that how many documents seem to you? Getting what you want—when, where, and how you want it—can be a real pain. That’s why we created this concise guide to getting around the obstacles that stand between you and the information your organization needs. Download the whitepaper to learn more. Sponsored by: ePharmaSolutions As clinical trials become more complex, safety document distribution to investigative sites has reached the point that demands a solution. Sponsored by: SAS In the quest to understand how a therapeutic intervention performs in actual use – in real medical practice outside the controlled environment of clinical trials – many life sciences organizations are stymied. Download now to read more. Sponsored by: Ashfield Healthcare December 5, 2017 | 2pm EST / 11am PST: Join this webinar to discover tested and proven solutions to manage vacancies. Presented by Tyler Cowan, VP, Client Solutions, Ashfield US, you’ll learn how to maintain and build momentum in field sales despite turnover. Sponsored by: Veeva CROs are leading an industry wide shift to modernize clinical systems and clinical trial processes. Presented By: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented By: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented By: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented By: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. Drug Development Primer November 9, 2017 | San Diego, CA Drug Development Immersion November 2-3, 2017 | Boston, MA BioBasics: Biotech for the Non-Scientist November 30-December 1, 2017 | Boston, MA CBI’s Commercial Data Insights 2017 November 28-29, 2017 | Philadelphia, PA Drug Development Boot Camp® 2017 November 15-16, 2017 | Boston, MA | 